Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics says initial portions of human trial deliver "positive results"

The tests, which are the precursor to the main element of the study, assessed irritancy and moisturisation potential
woman with skin!
The larger study, which kicks off later this month, involves 120 volunteer with dry skin

Initial human tests of SkinBioTherapeutics PLC's (LON:SBTX) SkinBiotix cream have confirmed the product’s safety as well as delivering positive data regarding irritancy and moisturisation potential.

These initial results are effectively a precursor to the main element of the study involving 120 volunteers with dry skin. This kicks off later in November and will assess the longer-term moisturisation potential of the technology.

The company found in a smaller trial with 30 people that there was no reaction, or irritation even at 20-times the standard dose. Concentrations were incrementally increased and the volunteers were monitored at one-, two- and three-day intervals.

Repetitive tests

In the repetitive, longer-term tests of a group of 31, in which the cream was applied for 12 hours using exaggerated exposure methods, one person experienced irritation, which the company said occasionally happens.  

“The irritation study results validate the safety element of our technology and provide further reasons for potential partners to speak to us,” said chief executive, Dr Cath O’Neill.

The second part of the three-stage test was to look at the moisturisation of SkinBiotix over 12 hours using a control group for comparison.

As in-house laboratory tests suggested the technology requires at least 24 hours to produce its effects, no difference between the groups was anticipated.

Good moisturisation

This proved to be the case. The cream containing SkinBiotix provided good moisturisation, which was generally higher than that provided by the control cream, but the difference was not significant, SkinBiotherapeutics said.

CEO O’Neill said the group had passed a “major milestone” by demonstrating the technology was safe, which allows for the commercialisation of the product.

She added: "We have always stated that we are a science-led company, therefore the larger moisturisation clinical trial that is due to commence later this month will be of key importance to us.

“We expect this data will demonstrate the long-term effects of our technology (greater than 24 hours) and the results will play a key part in the talks with commercial partners."

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use